Watch for the New Oral GLP-1 Agonist Orforglipron

May 2026

New Rx orforglipron (Foundayo) is the second ORAL GLP-1 receptor agonist approved for adults with overweight or obesity.

It’s another DAILY option...like oral semaglutide (Wegovy).

But orforglipron can be taken with or without food. Oral semaglutide must be taken with a max of 4 oz of water at least 30 minutes before the first food, other beverage, or oral meds of the day.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

GLP-1 Agonists Watch for the New Oral GLP-1 Agonist Orforglipron
Women's Health Estrogen Patch Shortages: How to Help
Rumor vs Truth Listen for Patient Questions About Gabapentin
Practice Help Offer Strategies to Improve Medication Taste
Seizures Improve Safety With Antiseizure Meds
Pain Brush Up on Non-Opioid Pain Medications
Dyslipidemia New Cholesterol Guidelines: Earlier Screening and More Meds
NatMed Spotlight Sort Out Claims About Lion’s Mane Mushroom

Watch for the New Oral GLP-1 Agonist Orforglipron

Practical advice for a better career, with unlimited access to CE

Table of Contents